Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777542 · ClinicalTrials.gov registry record · Phase 2
Treatment of Rett Syndrome With Recombinant Human IGF-1
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01777542 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 30 participants.
The verdict
NCT01777542, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Investigators are recruiting children for a clinical trial using the medication recombinant human IGF-1 (a.k.a. mecasermin or INCRELEX) to see if it improves the health of children with Rett syndrome (RTT). While IGF-1 is approved by the Food \& Drug Administration (FDA) for certain use in children, it is considered an investigational drug in this trial because it has not previously been used to treat RTT. Information from this study will help determine if IGF-1 effectively treats RTT but will not necessarily lead to FDA approval of IGF-1 as a treatment for RTT.
Interventions
- DRUG Placebo
- DRUG Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01777542
The ClinicalTrials.gov registry entry for NCT01777542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01777542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01777542 about?
NCT01777542 is a clinical study titled "Treatment of Rett Syndrome With Recombinant Human IGF-1". Investigators are recruiting children for a clinical trial using the medication recombinant human IGF-1 (a.k.a. mecasermin or INCRELEX) to see if it improves the health of children with Rett syndrome (RTT). While IGF-1 is approved by the Food \& Drug Administration (FDA) for certain use in children,...
What is the current status of trial NCT01777542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01777542?
The interventions under investigation include: Placebo (DRUG), Recombinant Human Insulin Growth Factor 1 (rhIGF-1) (DRUG).
Who is sponsoring clinical trial NCT01777542?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.